Abstract

Background: COVID-19 is a new form of Coronavirus which is resembling the same as SARS-CoV-2. This virus leads to cause severe respiratory diseases among the people. Coronavirus is declared as the pandemic by the WHO on March 11, 2020. Transmission of the disease is mainly due to the person to person contact by any means.

Materials and Methods:Wedetect the disease primary screening is necessary for a speedy recovery. PCR and other nucleic acid amplification are mainly used to diagnose the Covid-19. For the detection of the SARS, its gene is targeted in the amplification. The genes which are targeted are E, N, S, RdRp and ORf. Mutation in the SARS-CoV-2 genome is also detected by the various nucleic acid detection tests. Weimprove the detection of this pandemic, the only thing is to increase the involvement of Serological testing and molecular methods.

Results: The majority of 85-95% factor becomes useful to overcome this disease is early detection rate of the disease SARS-CoV-2.Molecular and serological findings should need to work simultaneously for the improvement in the diagnosis and the treatment approximately 85% laboratory.

Conclusion: The only factor which becomes useful to overcome this disease is early detection of the disease.Molecular and serologicalstudyshould need to work simultaneously for the improvement in the diagnosis and the treatment. The need of the hour is to maintain and introduced laboratory networking and its application.

Keywords: COVID-19; SARS-CoV-2; Laboratory Diagnosis; Molecular Method; Serological; Patients Management

References

1. Ai T., et al. “Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases”. Radiology (2020): 200642.
2. Center for Disease Control and Prevention. “Coronavirus disease 2019 (COVID-19) – transmission”. In: Center for Disease Control and Prevention (2020).
3. Center for Disease Control and Prevention. “Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings”. Centre for Disease Control and Prevention (2020).
4. Center for Disease Control and Prevention. “Interim Laboratory Biosafety Guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19)” (2020).
5. Center for Disease Control and Prevention. “Interim Guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19)”. Centre for Disease Control and Prevention (2020).
6. Hopman J., et al. “Managing COVID-19 in low- and middle-income countries”. The Journal of the American Medical Association (2020).
7. “Naming the coronavirus disease (COVID-19) and the virus that causes it” (2020).
8. “Novel coronavirus (2019-nCoV) situation reports” (2020).
9. “WHO Director-General’s opening remarks at the media briefing on COVID-19” (2020).
10. “WHO Director-General’s opening remarks at the media briefing on COVID-19 (2020).
11. “Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases” (2020).
12. “Guidelines for the safe transport of infectious substances and diagnostic specimens”. In: WHO (2020).
13. Wu Y., et al. “Prolonged presence of SARS-CoV-2 viral RNA in fecal samples”. Lancet Gastroenterology and Hepatology (2020).
14. Zhu N., et al. “A novel coronavirus from patients with pneumonia in China, 2019”. The New England Journal of Medicine 382 (2020): 727-733.
15. Padhi A., et al. “Laboratory Diagnosis of Novel Coronavirus Disease 2019 (COVID-19) Infection. In: Saxena S. (eds) Coronavirus Disease 2019 (COVID-19)”. Medical Virology: From Pathogenesis to Disease Control. Springer, Singapore (2020).
16. Guidelines for the safe transport of infectious substances and diagnostic specimens.
17. Arundhati Sharma., et al. “An Overview of Global Pandemic Covid-19 (Corona Virus)". International Journal of Research and Analytical Reviews (IJRAR) (2020).
18. Turner LH., et al. “Pre conceptual Zika virus asymptomatic infection protects against secondary prenatal infection”. PLos Pathogens 11 (2017): e1006684.
19. Zou L., et al. “SARS‐CoV‐2 viral load in upper respiratory specimens of infected patients”. The New England Journal of Medicine (2020).
20. Rothe C., et al. “Transmission of COVID‐19 Infection from an asymptomatic contact in Germany”. The New England Journal of Medicine 10 (2020): 970‐971.
21. Singer AJ., et al. “Comprehensive bedside point of care testing in critical ED patients: a before and after study”. American Journal of Emergency Medicine 6 (2015): 776‐780.
22. Prevention of CCfDCa. The guideline of diagnosis and treatment of COVID‐19.
23. Wan ZY., et al. “IFA in testing specific antibody of SARS coronavirus”. South China Journal of Preventive Medicine 3 (2003): 36‐37.
24. Lee HK., et al. “Production of specific antibodies against SARS‐coronavirus nucleocapsid protein without cross-reactivity with human coronaviruses 229E and OC43”. Journal of Veterinary Science 2 (2010): 165‐167.
25. Racine R and Winslow GM. “IgM in microbial infections: taken for granted?” Immunology Letters 2 (2009): 79‐85.
26. Guan WJ., et al. “Clinical characteristics of 2019 novel coronavirus infection in China”. Med Rxiv (2020).
27. National Health Commission of the People's Republic of China. Novel coronavirus pneumonia diagnosis and treatment protocol (5^th edition, trial).
28. Ho PL., et al. “A prediction rule for clinical diagnosis of the severe acute respiratory syndrome”. European Respiratory Journal 26 (2005): 474‐479.
29. Rainer TH., et al. “The spectrum of severe acute respiratory syndrome‐associated coronavirus infection”. Annals of Internal Medicine 8 (2004): 614‐ 619.
30. Xi M., et al. “Understanding the influence factors in viral nucleic acid test of 2019 novel coronavirus (2019‐nCoV)”. Chinese Journal of Laboratory Medicine 43 (2020): E002.

Citation

Citation: Mayadhar Barik., et al. “Molecular Screening and Diagnosis of SARS-CoV-2: Recent Advances and Future Prospective". Acta Scientific Microbiology 3.7 (2020): 46-51.

Copyright

Copyright: © 2020 Mayadhar Barik., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.